The Role of Polymorphism Gen Methylene Tetra Hydrofolate Reductase (MTHFR) C677T in Ischaemic Stroke Patients with and Without Hypertension

Stroke is a leading cause of disability and remains the second leading cause of death in the world. Some of the pathogenesis of stroke are interactions between genetic and acquired risk factors, the interaction is related with the atherosclerotic which is the main pathogenesis of ischaemic stroke. Previous studies demonstrated an association between methylene tetra hydro folate reductase (MTHFR) genotype and ischaemic stroke; the genotype is one of the independent risk factor. This study aims to know about the role of polymorphism gen in ischaemic stroke patients with and without hypertension. This study is a cross-sectional study, the sample was taken consecutively, after approval by the Medical Faculty Science's Ethics Committee at University Sumatera Utara. All sample matched with inclusion and exclusion criteria, demography data and blood sample were taken. Demography data were analysed using descriptive statistic. Of the 106 ischaemic stroke patients were divided into two groups, the first group is patients with hypertension (53 patients), and the second group is without hypertension (53 patients). We have done the PCR- RFLP to all the patients, we got 78 patients with of genotype, 23 patients with genotype and 5 patients with genotype. We found polymorphism is more frequent in ischaemic stroke patients with hypertension (16 patients; 69.5%), and all the patient with genotype are an ischaemic stroke with hypertension (5 patients; 100%). We concluded that polymorphism have an important role in hypertension and ischaemic stroke.